RNA vs. PTCT, CNST, ZGNX, ORIC, NKTX, ELAN, ROIV, INSM, LEGN, and ASND
Should you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include PTC Therapeutics (PTCT), Constellation Pharmaceuticals (CNST), Zogenix (ZGNX), ORIC Pharmaceuticals (ORIC), Nkarta (NKTX), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Insmed (INSM), Legend Biotech (LEGN), and Ascendis Pharma A/S (ASND). These companies are all part of the "medical" sector.
Avidity Biosciences (NASDAQ:RNA) and PTC Therapeutics (NASDAQ:PTCT) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends, valuation and community ranking.
PTC Therapeutics received 404 more outperform votes than Avidity Biosciences when rated by MarketBeat users. However, 64.62% of users gave Avidity Biosciences an outperform vote while only 61.83% of users gave PTC Therapeutics an outperform vote.
Avidity Biosciences has higher earnings, but lower revenue than PTC Therapeutics. Avidity Biosciences is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.
PTC Therapeutics has a net margin of -62.45% compared to Avidity Biosciences' net margin of -2,103.78%. PTC Therapeutics' return on equity of 0.00% beat Avidity Biosciences' return on equity.
Avidity Biosciences has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.
In the previous week, Avidity Biosciences had 4 more articles in the media than PTC Therapeutics. MarketBeat recorded 8 mentions for Avidity Biosciences and 4 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 1.33 beat Avidity Biosciences' score of 0.83 indicating that PTC Therapeutics is being referred to more favorably in the news media.
Avidity Biosciences currently has a consensus price target of $41.33, indicating a potential upside of 55.39%. PTC Therapeutics has a consensus price target of $35.67, indicating a potential downside of 2.34%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than PTC Therapeutics.
Summary
Avidity Biosciences beats PTC Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Avidity Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avidity Biosciences Competitors List
Related Companies and Tools
